Clovis Oncology Inc (NASDAQ:CLVS) is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with the placebo.
Based on the results, Clovis plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration during the second quarter.
